biostudies-literatureEissa HIntramural NIH HHSNCATS NIH HHSNIAID NIH HHSNHLBI NIH HHSNINDS NIH HHSNCI NIH HHS287-296https://www.ebi.ac.uk/biostudies/studies/S-EPMC11294800biostudies-literatureUnknown153(1)<h4>Background</h4>The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children in the United States and Canada onto a retrospective multicenter natural history study of hematopoietic cell transplantation (HCT).<h4>Objective</h4>We investigated outcomes of HCT for severe combined immunodeficiency (SCID).<h4>Methods</h4>We evaluated the chronic and late effects (CLE) after HCT for SCID in 399 patients transplanted from 1982 to 2012 at 32 PIDTC centers. Eligibility criteria included survival to at least 2 years after HCT without need for subsequent cellular therapy. CLE were defined as either conditions present at any time before 2 years from HCT that remained unresolved (chronic), or new conditions that developed beyond 2 years after HCT (late).<h4>Results</h4>The cumulativeThe Journal of allergy and clinical immunologyPosttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study.PMC11294800U01 AI126612ZIA AI001222P30 CA042014U10 HL069254UL1 TR002494UG1 HL069254KL2 TR002492U01 TR001263U54 AI082973U54 NS064808Griffith LMPai SYBurroughs LMBednarski JJHaddad ELogan BRBuckley RHChaudhury SAbdel-Azim HProckop SGoldman FDong HO'Reilly RJShereck EMalech HLGillio APQuinones ROved JHKohn DBDara JMolinari LHeimall JKnutsen AJyonouchi SCDeSantes KMousallem TINotarangelo LDEbens CLLeiding JCowan MJParrott REBleesing JHThakar MSMartinez CDorsey MYu LCPulsipher MARozmus JMoore TBRayes ABroglie LPuck JMForbes Satter LShah AJChandra SMarsh RAEissa HKapoor NChandrakasan SCuvelier GDEDavila Saldana BJChellapandian DKapadia MTorgerson TVander Lugt MTAquino VTeira PDvorak CCfalsePosttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study.<h4>Background</h4>The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children in the United States and Canada onto a retrospective multicenter natural history study of hematopoietic cell transplantation (HCT).<h4>Objective</h4>We investigated outcomes of HCT for severe combined immunodeficiency (SCID).<h4>Methods</h4>We evaluated the chronic and late effects (CLE) after HCT for SCID in 399 patients transplanted from 1982 to 2012 at 32 PIDTC centers. Eligibility criteria included survival to at least 2 years after HCT without need for subsequent cellular therapy. CLE were defined as either conditions present at any time before 2 years from HCT that remained unresolved (chronic), or new conditions that developed beyond 2 years after HCT (late).<h4>Results</h4>The cumulative2024-01-01T00:00:00Z2024 Jan2026-06-02T13:09:11.546Z2026-04-18T03:11:21.34ZS-EPMC112948003779357210.1016/j.jaci.2023.09.027